Form 4: Axsome Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Susan Mahony acquired 5,799 stock options in Axsome Therapeutics on June 7, 2024, exercisable starting June 7, 2025.
Summary
- On June 7, 2024, Susan Mahony, a director of Axsome Therapeutics, acquired 5,799 stock options.
- The exercise price of these options is $73.90.
- The options vest in full on June 7, 2025, one year after the grant date.
- The options expire on June 7, 2034.
- Following the transaction, Mahony directly owns 5,799 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining market confidence.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of transaction: Director Susan Mahony acquired stock options. |
| 06/07/2025 | Vesting date: Options vest in full one year after the grant date. |
| 06/07/2034 | Expiration date: Options expire ten years after the grant date. |
| 06/11/2024 | Date of signature of the form. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.